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Objective: Cancer patients, particularly those prescribed with oral oncolytic medications, face
treatment side effects and temporary and permanent stoppages of treatment. This research
examines how events during treatment affect patients' beliefs regarding oral oncolytic
medications.
Methods: A total of 272 cancer patients initiating 1 of 28 oral oncolytic agents were followed
for 12 weeks. Assessments of Beliefs About Medications Questionnaire, symptoms, physical
function, and depression measures were performed during telephone interviews at intake (med-
ication start) and 4, 8, and 12 weeks. Electronic medical record audits identified dates of tempo-
rary and permanent medication stoppages. Linear mixed‐effects models were used for
longitudinal analyses of the Beliefs About Medications Questionnaire scores in relation to patient
characteristics, symptom severity, and medication stoppages.
Results: Over the initial 12 weeks, beliefs about the necessity of oral medications have
increased, concerns have decreased, and interference of medications with daily lives has
increased. Permanent stoppage of a medication predicted significant declines in beliefs about
its necessity over time. Male patients, those less educated, those reporting higher symptom
severity, and those experiencing temporary stoppages had greater concerns. Interference of med-
ications with daily life was higher for males, increased with higher symptom severity, and differed
by drug category.
Conclusions: Patients' beliefs in the necessity of their oral medication were affected only by a
permanent drug stoppage. Symptom severity, education, and patient sex affected patients' beliefs
about their concerns with their medications and the interference medications posed for their
daily lives. Interventions may need to target the distinct dimensions of beliefs during treatment
with oral oncolytic agents.
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Patients with advanced cancers for whom earlier lines of treatment
have failed are frequently prescribed with oral oncolytic agents includ-
ing oral cytotoxic drugs, inhibitors directed at cell surface receptors,
and those targeted at the tumor microenvironment.1 A number of fea-
tures set these medications apart from medications for other chronicwileyonlinelibrary.com/jourconditions. Oral oncolytic medications are typically expensive with a
cost of hundreds of United States (US) dollars per dose and, although
covered by many health insurances in the US, require out‐of‐pocket
costs that could be in thousands of dollars. These medications may
produce severe symptoms and side effects that patients experience
at home without frequent contacts with oncology professionals. In
response to these symptoms and side effects, oncologists may adjustCopyright © 2017 John Wiley & Sons, Ltd.nal/pon 1005
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tinuation of the oral oncolytic agent. This research focuses on examin-
ing factors that influence patients' beliefs about oral oncolytic
medications as they proceed through the first weeks of treatment.
Horne and colleagues2,3 developed measures of patients' beliefs
regarding the necessity of their medications and concerns that arise
from their impact on functioning and health. The Beliefs about Medi-
cines Questionnaire (BMQ) is grounded in social cognition as
expressed through the health belief model and assesses patients' pos-
itive outcome expectancy (benefits from treatment) and the accompa-
nying concerns regarding the use of medications and their interference
with daily activities.4-6 Patients' scores on the necessity and concerns
subscales have been found to be associated with their levels of
adherence2,7-9 as well as with their sex, symptom reports, duration of
treatment, number of medications, and depression.7,10-17
This research examines how events arising during the course of
treatment together with patients' factors alter beliefs regarding the
necessity and concerns attributed to their medications. Identifying
the effects of these events and patient factors could inform the
development and tailoring of interventions to support adherence to
and persistence of oral oncolytic treatment.
This report is based on the secondary analysis of data from a
recently completed trial of an intervention to improve adherence and
symptom management among patients' newly prescribed oral
oncolytic medication.18 Briefly, adherence was high and did not differ
by trial arm, while symptoms were improved in the experimental arm.
The important feature of this trial is the timing of data collection begin-
ning with the initiation of the new oral oncolytic agent and through the
first 12 weeks. We assess these data to determine how medication
beliefs change over these initial 12 weeks and how patient, disease,
and treatment factors influence the beliefs over time.2 | METHODS
2.1 | Design and sample
A total of 272 patients were accrued from 6 national cancer institute–
designated comprehensive cancer centers in the US (Figure 1). The
study was approved by the Institutional Review Board (IRB) of
Michigan State University (IRB# 13‐076 M) and the IRBs of each
cancer center. All patients had had health insurance coverage
that was private and/or government‐sponsored (Medicaid, Veterans
Administration, Medicare for those 65 years of age or older). Patients
were identified when first prescribed at least 1 of 28 oral anticancer
agents approved by the Food and Drug Administration. Recruiters at
each cancer center were trained in how to approach patients and
introduce the study. Eligible patients were cognitively intact; had a
Karnofsky score of 50 or higher or an ECOG score of 0 to 2; had a
landline or cellular telephone; were able to speak and read English;
and had appropriate level of hearing for telephone contacts. If patients
agreed to participate, they signed the consent form and received a
folder with complete study information including who to call with
questions. Recruiters entered all patient information and drug name
and dosage into a secure electronic tracking system, and interviewersconducted baseline interviews shortly after patients had received
their medication from the specialty pharmacy and started taking it.
Following the intake interview, patients were randomized to either
the experimental or control arm. A minimization program was used to
balance treatment arms by accrual location, cancer site, continuous
vs intermittent dosage, concurrent intravenous chemotherapy, and
depression. All patients received interviews at 4, 8, and 12 weeks
and weekly automated calls to assess symptoms and adherence to
their oral oncolytic agents. Patients randomized to the experimental
arm received daily telephone reminders to take their medications
and a printed copy of the Medication Management and Symptom
Management Toolkit (toolkit). During weekly calls, patients in the
experimental arm were advised to consult the toolkit for each
symptom they scored at a 4 or higher in severity on a 0 to 10 scale.
This toolkit described 18 common symptoms associated with cancer
and treatment using oral anticancer agents. It was organized by
frequently asked questions and presented evidence‐based advice on
how to manage the symptom and when (at what severity levels) to
inform the oncologist. The toolkit also offered suggestions on manag-
ing oral anticancer medication and enhancing adherence.2.2 | Measures
All measures were administered at intake, 4, 8, and 12 weeks, with the
exception of demographics and comorbid conditions, which were
assessed at intake only. If oral cancer medication was stopped, and
the patient did not take the medication in any of the 4‐week period
between interviews, medication‐related instruments including the
BMQ were not administered.2.2.1 | Beliefs about medicines (BMQ)
Originally, the instrument contained 10 items,3 each rated on a 1‐to‐5
(strongly agree to strongly disagree) scale. Five items loaded onto the
necessity subscale and 5 onto the concerns subscale. In 2004, the
11th item was added, focusing on unpleasant side effects.19 For this
research, 11 items were included, each with reference to “oral cancer
medications.” All items were submitted to an exploratory factor analy-
sis at each of the 4 observations. Five necessity items were loaded
consistently on the necessity subscale at each observation. However,
at each observation, the original concern items separated into 2 unique
subscales, one of which was labeled the concerns subscale, and the
other one was labeled interference subscale. The concerns subscale
included worry about having to take medications, worry about long‐
term effects, “medications are a mystery to me,” and worry about
becoming too dependent. The interference subscale comprised of 1
item from the original concerns subscale (“my medications disrupt my
life”) and 1 item from the later version of the instrument (“my medica-
tions give me unpleasant side effects”). Factor loadings for these 3 sub-
scales remained stable at each of the 4 time points. Therefore, 3
subscale scores—necessity, concerns, and interference—were computed
at each observation by averaging the corresponding item scores.
Reverse scoring of items assured that higher scores on each subscale
indicated greater necessity, concerns, or interference. The internal
consistency reliability (Cronbach alphas) for each subscale at 4 time
FIGURE 1 Oral adherence consort table. IVR, interactive voice response
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concerns; and .75, .80, .70, and .75 for interference.
2.2.2 | Symptoms
The presence, severity, and interference with daily activities were
measured for 18 prevalent symptoms including pain fatigue, sleep
disturbance, anxiety, weakness, headaches, skin rash, numbness or
tingling, redness or peeling in hands or feet, swelling of hands and feet,
joint/muscle pain, mouth sores, lack of appetite, nausea or vomiting,
diarrhea, constipation, cough, and shortness of breath. Patients indi-
cated if they had experienced the symptom in the past 7 days and, if
yes, rated severity of the symptom on a scale from 1 to 9 and interfer-
ence of that symptom with daily activities on a scale of 0 (did not
interfere) to 9 (interfered completely). Summed symptom severity
and summed symptom interference indices were derived across the
array of symptoms.2.2.3 | Depressive symptoms
Depressive symptoms were assessed using the Center for Epidemio-
logic Studies Depression (CES‐D) 20‐item scale.20 Cronbach alpha
exceeded .90 in this sample.2.2.4 | Physical function
Physical function was measured21,22 using the Patient Reported Out-
comes Measurement Information System Short Form 10 (Cronbach
alpha exceeded .90).2.2.5 | Demographic characteristics
Demographic characteristics including age, sex, race, ethnicity, and
level of education were obtained during baseline interview. Level of
education was summarized as high school or less, some to 4‐year
college education, or graduate/professional degree.
1008 SIKORSKII ET AL.2.2.6 | Comorbid conditions treated with medications
Comorbid conditions treated with medications at intake into the
trial were identified via electronic medical record (EMR) audits.
The medications documented in the EMR prior to the prescription
date for the oral oncolytic medication were used to identify the
corresponding comorbid conditions. Based on the purpose of the
drug, conditions included cardiovascular problems, chronic lung dis-
ease, asthma, kidney disease, diabetes, depression, and arthritis. If
multiple medications were prescribed for the same condition, the
condition was counted once.
2.2.7 | Oral oncolytic agents
Oral oncolytic agents were collapsed into 4 categories: cytotoxic
agents, kinase inhibitors, sex hormone inhibitors, and others (see
Appendix A). Dosages of these oral oncolytic medications were either
continuous (taken every day) or intermittent (medication taken
followed by rest periods).
2.2.8 | Treatment stoppages
Treatment stoppages were based on start date as documented in
the EMR and then assigned to a corresponding 4‐week time: baseline
to weeks 4, 4 to 8, or 8 to 12. Temporary stoppages were differenti-
ated from permanent stoppages based on information in the EMR
for each oral oncolytic agent. Patients could experience multiple
temporary stoppages but only 1 permanent stoppage. Temporary or
permanent stoppage during each 4‐week period was defined by at
least one of the drugs in the protocol being stopped temporarily or
permanently, respectively, in that period. We were unable to identify
dose reductions in a uniform manner across sample for 2 reasons. First,
reductions had to be calculated for each drug among multiple ones
taken by a patient. Second, many oncolytic agents had intermittent
dosing (3 weeks on 1 week off), and dose reductions could occur
via directing the patient to take a smaller dose or by extending or
adding rest periods.3 | STATISTICAL ANALYSIS
The distributions of the BMQ subscale scores and other variables
were summarized with descriptive statistics. Correlations among
the BMQ subscales were computed at each time point. Longitudinal
mixed‐effects models were used to relate 4 repeated measures
(baseline, 4, 8, and 12 weeks) of each of the 3 BMQ subscale
scores to the following fixed explanatory variables: patient's age,
sex, drug category, level of education, number of comorbid condi-
tions treated with medications at intake, and trial arm. Since the
intervention was not directed at beliefs about medications, we did
not expect differences by trial arm but, nevertheless, adjusted for
it in this secondary analysis. Time was entered as a categorical var-
iable with levels—intake: 4, 8, and 12 weeks—to model potentially
nonlinear patterns in the BMQ scores over time. Summed symptom
severity as calculated at baseline 4, 8, and 12 weeks was entered
as a time‐varying covariate. Next, the presence or absence of per-
manent or temporary stoppages in each observation period (1 stop-
page variable at a time) was added as a time‐varying covariate.Finally, we explored adding the physical function and CES‐D scores
as additional time‐varying factors to gauge their effects on the
BMQ over and above symptom severity. Least square means of
the BMQ subscale scores according to time and drug category
were output from the mixed models, and differences among them
were tested. All statistical tests were 2‐sided. The analyses were
conducted in SAS 9.4.4 | RESULTS
The sample had equal representation of males and females, and a
mean age of 61 years (Table 1). At intake, health insurance cov-
ered oral oncolytic medication for 89% of patients. Fifty three per-
cent of patients had out‐of‐pocket cost at intake (median $25,
range $1‐$8300). Cytotoxic agents and kinase inhibitors accounted
for most 28 oral agents prescribed at intake. Of 27 patients on
sex hormone inhibitors, 26 were men with prostate cancer over
60 years of age. The average number of comorbid conditions
treated with medications at intake was 3.38, with an average of
12 medications prescribed to patients for those conditions
(Table 1).
Based on the unadjusted means of the BMQ subscales (Table 1),
patients' beliefs about the necessity and interference of their oral anti-
cancer medications rise over the 12 weeks while concerns decline. Each
subscale appears to assess a unique construct. Necessity did not corre-
late with either concerns or interference, with Pearson correlation coef-
ficients below 0.20 at each observation. Correlations between
interference and concerns were 0.36 at intake, 0.28 at week 4, 0.31 at
week 8, and 0.43 at week 12.
The highest rate of temporary stoppages of the oral agents was in
the first 4 weeks of treatment (22%) then declined for the subsequent
two 4‐week periods. In contrast, permanent stoppages of oral agents
were fairly stable with a slight decline from 11% in the first 4 weeks
to 8% during weeks 8 to 12 (Table 1).
The multivariable longitudinal model for the necessity scores
revealed that they were significantly higher at week 12 compared to
intake, with the adjusted mean difference of 0.11, standard error of
0.05, and P = .02 (first panel of Table 2). Level of education was a
significant predictor of perceived necessity; those with some to com-
pleted college had lower necessity scores than those with graduate
or professional degrees or high school or less education. Patients on
cytotoxic agents reported lowest necessity scores compared to other
drug classes. Permanent stoppages of oral agents had a strong
negative effect on necessity beliefs, with significant reductions in
perceived necessity following oral agent stoppages (mean reduction
of 0.50, standard error = 0.10, P < .01, Table 2). Age, sex, number of
comorbid conditions treated with medications, trial arm, and symptom
severity did not affect necessity over and above education, time, drug
category, and permanent stoppages.
Concerns declined significantly over the first 4 weeks following
oral agent initiation then remained stable over time (Figure 2 and
Table 2). Male patients, those less educated, and those who reported
greater symptom severity and temporary stoppages were more con-
cerned about the impact of their medications. In contrast, patients
TABLE 1 Descriptive statistics for the study sample
Characteristic N (%)









Hispanic or Latino 5 (2%)
Not Hispanic or Latino 260 (95%)
Unknown 7 (3%)
Level of education
High school or less 71 (26%)
Some college or completed college 150 (55%)
Graduate or professional degree 49 (18%)
Unknown 2 (1%)
Health insurance coverage for oral oncolytic medication
Yes 241 (89%)
No 18 (6%)
Don't know 13 (5%)
Drug category
Cytotoxic agents 95 (35%)
Kinase inhibitors 127 (47%)






























Number of medications other than oral oncolytics
prescribed at intake or during the study
11.81 (5.90)
Out‐of‐pocket cost for oral oncolytic medication 257.82 (925.53)
BMQ necessity 3.70 (0.70)
BMQ concerns 2.66 (0.78)
BMQ interference 2.50 (0.97)
Symptom severity 24.76 (22.00)
Physical function 45.20 (7.87)
CES‐D 9.76 (8.97)
Week 4 (N = 233 completed interview, N = 222 completed BMQ)
BMQ necessity 3.62 (0.77)
BMQ concerns 2.51 (0.76)
BMQ interference 2.67 (1.1)
Symptom severity 22.61 (21.43)
Physical function 44.94 (8.39)
CES‐D 9.69 (8.75)
Had a temporary drug stoppage, N (%)a 57 (22%)
Had a permanent drug stoppage, N (%)a 28 (11%)
Week 8 (N = 208 completed interview, N = 186 completed BMQ)
BMQ necessity 3.72 (0.77)
BMQ concerns 2.47 (0.77)
BMQ interference 2.63 (1.00)
Symptom severity 18.82 (16.18)
Physical function 45.35 (7.92)
CES‐D 9.15 (8.21)
Had a temporary drug stoppage, N (%)a 30 (12%)
Had a permanent drug stoppage, N (%)a 24 (9%)
Week 12 (N = 214 completed interview, N = 164 completed BMQ)
BMQ necessity 3.80 (0.87)
BMQ concerns 2.47 (0.77)
BMQ interference 2.62 (1.04)
Symptom severity 17.99 (17.58)
Physical function 45.58 (8.45)
CES‐D 9.52 (8.83)
Had a temporary drug stoppage, N (%)a 12 (5%)
Had a permanent drug stoppage, N (%)a 18 (8%)
Abbreviations: BMQ, Beliefs About Medications Questionnaire; CES‐D,
Center for Epidemiologic Studies Depression.
aPercent is out of the number of patients with available medical record
audit data for each period: N = 272 at intake, N = 265 at week 4,
N = 255 at week 8, and N = 234 at week 12.
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the impact of their medications.
Interference scores increased significantly between baseline and
week 4 then were relatively stable between weeks 4 and 12
(Figure 2 and Table 2). Higher symptom severity and male sex were
associated with greater interference.
When physical function and CES‐D scores were added to the lon-
gitudinal models as time‐varying covariates, they were not significant
and did not appreciably change the effects of other variables, therefore
were not included in the final models.
TABLE 2 Longitudinal models for BMQ subscales: coefficients, SEs, and significance of the effects of the explanatory variables
Necessity Concerns Interference
Explanatory Variable Coefficient (SE) T P Coefficient (SE) T P Coefficient (SE) T P
Age −0.0027 (0.28) −0.80 0.42 0.0011 (0.003) 0.33 .74 0.0009 (0.004) 0.23 .82
Number of comorbid
conditions
−0.02 (0.02) −0.98 0.33 0.02 (0.02) 0.84 .40 0.03 (0.02) 1.62 .11
Sex
Male −0.13 (0.08) −1.60 0.11 0.20 (0.08) 2.57 .01 0.17 (0.09) 1.95 .05
Female (ref)
Trial arm
Experimental 0.09 (0.08) 1.21 0.23 −0.05 (0.07) −0.72 .47 −0.05 (0.08) −0.58 .56
Control (ref)
Symptom severity 0.0005 (0.001) 0.35 0.73 0.006 (0.0013) 4.54 <.01 0.02 (0.002) 13.24 <.01
Time
Week 4 −0.04 (0.05) −0.84 0.39 −0.15 (0.05) −2.87 <.01 0.23 (0.07) 3.23 <.01
Week 8 0.04 (0.06) 0.66 0.51 −0.14 (0.06) −2.28 .02 0.31 (0.08) 3.80 <.02
Week 12 0.11 (0.05) 2.28 0.02 −0.16 (0.04) −3.49 <.01 0.29 (0.07) 4.33 <.01
Intake (ref)
Drug category
Cytotoxic agents −0.25 (0.14) −1.73 0.08 −0.14 (0.14) −0.99 .32 0.55 (0.15) 3.61 <.01
Kinase inhibitors −0.07 (0.14) −0.48 0.60 0.07 (0.14) 0.54 .60 0.45 (0.15) 3.01 <.01









−0.06 (0.12) −0.51 0.61 −0.60 (0.11) −5.33 <.01 −0.24 (0.12) −1.90 .06
Some or completed
college
−0.22 (0.10) −2.39 0.02 −0.22 (0.09) −2.47 .01 0.02 (0.10) 0.26 .80
High school or less (ref)
Abbreviations: BMQ, Beliefs About Medications Questionnaire; SE, standard error.
FIGURE 2 Least square means for the Beliefs About Medications
Questionnaire necessity, concerns, and interference at 4 time points
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A new generation of oral oncolytic agents is transforming cancer treat-
ment. At least a quarter (1/4) of all cancer agents in development are
oral agents. Therefore, it is important to understand how events arisingduring treatment with oral oncolytic agents affect patients' beliefs
regarding the necessity, concerns, and interference they attribute to
these medications. Consistent with other findings,23 the 3 subscales
have low to moderate interscale correlations, indicating that they
reflect distinct constructs that change differently over time.
Patients' beliefs in the necessity of their medications did not change
in the first 4 weeks then increased significantly betweenweeks 4 and 12.
Concerns about medications declined in the first 4 weeks, with no
change in weeks 8 to 12, and beliefs about medication interference
steadily increasedover time.With respect to necessity, the initial 4weeks
following the initiation of treatment appeared to be a time for delibera-
tion. Following this initial period, patients altered their beliefs (stronger
beliefs in the necessity of their medications, except for those where the
medications were stopped; fewer concerns about its impact on future
health; and a realization that the medications interfere with daily activi-
ties). However, changes in these beliefs are grounded in the events sur-
rounding treatment. As symptom severity worsens, patients report
greater concerns about how medications may affect their future health.
Increasing symptom severity does not appear to affect beliefs about
SIKORSKII ET AL. 1011necessity and may indicate that the treatment is working, and thus,
medication is necessary to manage the cancer.
This research is among the first to show how patients' beliefs in
the necessity of their medications decline when medications are
withdrawn by the physician. Consistent with several cross‐sectional
studies of beliefs about different medication types,16,24 we found that
treatment interruptions may give rise to concerns that oral oncolytic
agents are no longer managing their disease. At least 2 lines of expla-
nation might be pursued. First, patients' beliefs regarding a medica-
tion may be mediated by oncologists' views of its efficacy. This
explanation25 points to the pivotal role that oncologists play in defin-
ing the necessity of treatment. Second, once stopped, patients may
disavow the necessity of their medication as a form of reducing
cognitive dissonance. While speculative, these explanations may
guide future research regarding abrupt shift in necessity once cancer
treatments are stopped.
Patients' concerns prompted by treatment interruption may pro-
duce a different type of reaction than concerns resulting from worsen-
ing symptoms. Interruptions suggest to patients that the medication is
not tolerable while increasing symptoms may engender mixed reac-
tions; on one hand, symptoms may indicate that the drug is working
but concerns may be rising because patients may be unable to endure
the consequences of the medication. Similar lines of research using
other chronic diseases have reported how lack of self‐efficacy was
related to beliefs about necessity and concerns.13,26 These data indi-
cate that concerns regarding oral agents arise from different sources.
Future research needs to explore how patients interpret and act upon
concerns depending upon the factors that gave rise to them.
Regarding the effects of other factors on beliefs, differences
according to sex and level of education were found, but comorbidity
did not affect beliefs over and above other factors in longitudinal
models. These findings are in contrast with those in type 2 diabetes,
where differences in necessity beliefs by sex and comorbid conditions
were found among patients on antihypertensive medications.26 Lack of
differences by sex and comorbidity in this study could be because of
the difference in populations and the fact that oral oncolytic medica-
tions are often prescribed as the last available line of treatment. On
the other hand, our findings on the influence of education on beliefs
are similar to those reported among people with asthma.27
Finally, there were no effects of the adherence reminder and
symptom management intervention on beliefs over and above symp-
tom severity. This finding was expected because the intervention
was not directed toward altering beliefs.6 | CONCLUSIONS
In summary, patients' beliefs about the necessity of their cancer treat-
ments are high, increase over time, and decline only when medications
are permanently stopped. Male patients, those who report increasing
severity of their symptoms, and those who experience temporary stop-
pages of their medications report increased concerns and interference
of their medications with their lives. Since these factors remain signif-
icant in the multivariable model, they represent relatively independent
contributions toward patients' level of concern.6.1 | Limitations
The small numbers of racial and ethnic minorities limited assessment of
how these variables affected beliefs. The follow‐up period was very
short given the long‐term treatment among patients on these medica-
tions. Finally, during this short period, adherence was high and had lit-
tle variation, which precluded the examination of the effects of beliefs
on adherence.
6.2 | Clinical implications
Oncologists could be made aware of how medication adjustment
occurs over time, introduce supportive and end‐of‐life care, and pres-
ent it as a valuable next line of cancer management. Providers of sup-
portive and end‐of‐life care could address patient beliefs about oral
oncolytic medications as part of comprehensive patient care as
patients move toward the end of life.
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